PREVIOUS
Newsletter # 111
In vivo studies
Cariprazine (sold under brand names Vraylar, Reagila, or Symvenu) is an atypical antipsychotic used to treat schizophrenia and bipolar disorders. Unlike other oral antipsychotics, it produces two active metabolites, one of which has an extended half-life, contributing to its clinical effectiveness.
Cognitive deficit is also a core feature of schizophrenia and can be particularly challenging to treat. Indeed, while antipsychotic medications are often effective in managing positive symptoms (such as hallucinations and delusions) and some negative symptoms (such as avolition), they may have limited impact on cognitive deficits.
1.
Neurofit data show that in Phencyclidine (PCP)-treated mice, an accepted animal model of schizophrenia, Cariprazine significantly improved the associated cognitive deficit. These data are supportive of a couple of findings stating the superiority of Cariprazine over other antipsychotics, as reviewed by Olivola and al. 2023
-
-
Cariprazine treatment restores the cognitive ability of PCP-treated mice
The graph shows the cognitive performance of mice as measured by their spontaneous alternation in the T-maze. Due to the adverse psychological effects of PCP (memory and attention impairment, confusion, and disorientation), a dramatic decrease in the spontaneous alternation of mice is observed (white vs black column).
The administration of Cariprazine increases in a dose-dependent manner the spontaneous alternation performance of PCP-mice, hence reflecting an improved cognitive ability (black vs blue columns).
*, p ≤ 0.05 and ***, p ≤ 0.005 : significantly different as compared to the PCP/vehicle (PCP/ 0 mg/kg) group
Get in touch
